LB 2102
Alternative Names: LB-2102Latest Information Update: 17 Jun 2025
At a glance
- Originator Legend Biotech USA
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Small cell lung cancer